How Immunotherapy Doses Are Calculated: mg/kg vs Flat Dose
Most immune checkpoint inhibitors are now given as a fixed milligram dose that is the same for a 50 kg patient and a 90 kg one. Chemotherapy is not. That difference surprises almost everyone, it is deliberate, and it has a direct effect on what a cycle costs. This page explains the conventions. It cannot tell you your dose.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
Why is the pembrolizumab dose 200 mg for everyone?
Because for this class of medicine, giving more drug past a certain point does not add effect. Pembrolizumab was originally studied at doses set per kilogram. Modelling of that trial data showed a fixed 200 mg dose produces a drug-exposure distribution comparable to the weight-based dose, so regulators accepted the simpler fixed dose.
The underlying reason is a plateau. A checkpoint inhibitor works by occupying the PD-1 receptor on T cells and keeping it blocked. Once essentially all the available receptor is occupied, adding more antibody does not block anything further. Published analyses of the pembrolizumab programme, including work by Freshwater and colleagues in 2017, reported that 200 mg and 2 mg/kg gave similar exposure distributions with no advantage to either approach.
Once that is true, the case for weighing every patient and computing an individual dose weakens considerably. A fixed dose is faster to prepare, easier to check and much harder to get wrong. Pharmacy errors in oncology cluster around calculations, so removing a calculation removes a category of error.
What follows are the conventions you will see printed on a prescription. They are published label conventions, not a dose for you.
Summarised from published prescribing information and regulator approval notices, checked August 2026, and simplified for reading. Labels differ by indication and by country, and the label your treating team is working from is the one that counts. This table is an orientation, not a prescribing reference.
Does your body weight change the immunotherapy dose?
For most checkpoint inhibitors given on their own to an adult, no. The fixed dose is the same whether you weigh 50 kg or 90 kg. Weight still matters in four situations: certain molecules, certain combinations, adults below a stated weight threshold, and children.
Patients who have been through chemotherapy find this genuinely hard to believe, and they are right to be surprised. In chemotherapy, height and weight are measured, body surface area is calculated, and the dose follows from it. Being told that immunotherapy simply uses the same number for everyone sounds like a shortcut.
It is not a shortcut. It is a consequence of how the two kinds of drug behave. A cytotoxic chemotherapy drug has a narrow margin between an effective dose and a harmful one, so scaling matters. A monoclonal antibody such as a checkpoint inhibitor distributes in a much more predictable way, has a wide margin, and reaches a ceiling of effect. Scaling it to body size buys precision that changes nothing.
One practical consequence is worth knowing. If you lose or gain a substantial amount of weight during treatment, a fixed-dose medicine will usually not change, while a weight-based one usually will be recalculated. Neither is something to assume. Report a significant weight change and let the team decide what, if anything, follows from it.
If a dose on your prescription looks different from the conventions above, that is not in itself a mistake. Indication, combination partner, trial protocol and local label all legitimately change the number. Ask the treating team to explain it rather than comparing it with a page on the internet.
Why do vial sizes matter so much?
Because these medicines are bought and billed by the vial, not by the milligram. A dose is made up from whole vials, and the vial sizes on the market determine how neatly a dose fits. Where it does not fit, the leftover is usually paid for and usually discarded.
This is the hidden mechanism behind a lot of confusing immunotherapy bills, and it is worth understanding before you look at one. Three things interact.
- The vial size. Several checkpoint inhibitors are supplied in 100 mg vials, which is why so many conventional doses are round multiples of 100 mg. Toripalimab’s Indian vial is 240 mg, which matches its conventional dose in a single vial.
- Whether the dose is fixed or weight-based. A fixed dose is a fixed number of vials, every cycle, for every patient. A weight-based dose is not, and it can leave a part-vial that still has to be bought.
- Whether the leftover can be used. Once opened, a single-dose vial has a short window and strict handling conditions. Some hospital pharmacies operate a formal dose-banding or vial-sharing arrangement to reduce waste; many cannot, for good safety reasons.
None of this is something a patient should try to optimise. It is, however, something worth asking about, because a pharmacy that runs a dose-banding programme can sometimes explain a difference between two quotations that otherwise looks arbitrary.
Never accept an offer to split a vial between patients outside a hospital’s own controlled arrangement, and never accept a part-used vial from an outside source. Sterility, cold chain and traceability all depend on that not happening.
What this page cannot tell you, and who it does not apply to
This page cannot tell you your dose, and it should not be used to check one. It describes the general conventions written into published labels so that a prescription is less baffling. Working out an actual dose is a clinical calculation made from your diagnosis, your weight on the day, your organ function, your other medicines and the exact regimen you are on. Only your treating oncology team can do it, and only they can change it.
The general conventions described here specifically do not apply in these situations:
- Children and adolescents. Paediatric dosing of checkpoint inhibitors is weight-based even where the adult dose is fixed. Nothing on this page transfers to a child.
- Adults below about 30 kg. Some labels, durvalumab’s among them, switch back to weight-based dosing below a stated body-weight threshold precisely because a fixed dose would over-expose a very small adult.
- Combination regimens. When a PD-1 antibody is combined with ipilimumab or with chemotherapy, the dose and interval of one or both drugs can differ from the single-agent convention. The combination label governs, not the single-agent one.
- Antibody-drug conjugates and older antibodies. Trastuzumab, trastuzumab deruxtecan and rituximab are dosed by body weight or body surface area. They follow a different rule set entirely.
- Anyone with organ impairment or an ongoing immune-related adverse event. What happens next in that situation is a holding, steroid and monitoring decision, not an arithmetic one.
- Anyone tempted to reduce, split, delay or skip a dose on cost grounds. This is the most important line on the page. Do not do it, and do not ask a pharmacy to do it. Raise the cost problem with the treating team openly instead — there are legitimate routes to discuss, and an improvised dose is not one of them.
If your weight has changed substantially since treatment started, tell your team rather than assuming the dose should follow. For a fixed-dose medicine it usually does not; for a weight-based one it usually does; and which of those you are on is exactly the kind of thing worth asking at the next visit.
Does the dosing method change what you pay?
Yes, and in a way that feels unfair to lighter patients. With a fixed dose, a 50 kg patient buys exactly the same number of vials as a 90 kg patient. Under the older weight-based convention, the lighter patient would have needed less drug. Fixed dosing removed that difference.
This is the real question behind most searches for “200 mg flat dose vs weight based”, so it deserves a direct answer rather than a diplomatic one. The published economic literature has made this point for years: for a slightly built patient, fixed dosing costs more drug than a per-kilogram calculation would have. Regulators weighed that against error reduction, preparation time and the flat exposure-response relationship, and settled on fixed dosing.
Two further points shape the bill more than the dosing convention does.
- The interval matters as much as the dose. A fortnightly medicine is roughly 26 doses a year; a three-weekly one is roughly 17. A six-weekly option with double the milligrams is usually about the same drug cost per year, but far fewer hospital visits — which is its own kind of saving for someone travelling in from outside the city or holding down a job.
- The drug is only part of the bill. Day care, nursing, pre-cycle blood tests, response-assessment imaging and any chemotherapy given alongside are billed separately. Response-assessment imaging is generally coordinated at partner imaging centres rather than performed in-house.
No price is quoted on this page against any named molecule. Any figure you are given should be dated, itemised, in writing, and traceable to the pharmacy or hospital issuing it — with the drug separated from the day-care, nursing, laboratory and imaging lines. Ask your insurer separately what is covered before the first cycle, not after it.
Which cancer antibodies are still dosed by weight?
Plenty of them. The move to fixed dosing happened within the checkpoint-inhibitor class and did not spread to every antibody used in cancer. If your prescription has more than one biological on it, the two may well follow different rules.
Trastuzumab is dosed per kilogram of body weight, with a higher first dose followed by a lower maintenance dose at each subsequent cycle. Rituximab is dosed by body surface area, the same measure chemotherapy uses, which means height as well as weight goes into the calculation. Ipilimumab, although it is a checkpoint inhibitor, kept per-kilogram dosing throughout. Serplulimab, one of the newer PD-1 entrants approved in India, is also weight-based.
The practical implication is small but useful: on a mixed regimen, do not expect the numbers to behave consistently, and do not read a change in one drug’s dose as implying anything about another.
For the detail on two of these, Trastuzumab and Trastuzumab Deruxtecan in Breast Cancer covers the weight-based antibody most often prescribed alongside other treatment, and Rituximab: Uses, Cost and Side Effects covers the body-surface-area convention that came from chemotherapy practice.
Can an immunotherapy dose be reduced if you get side effects?
Generally not in the way chemotherapy doses are reduced. For immune checkpoint inhibitors, side effects are managed by holding the next dose, treating the inflammation, and deciding whether to restart — not usually by giving a smaller amount of the same drug.
The logic follows from the plateau again. If the effect does not increase above a certain exposure, then a lower dose is unlikely to reduce the immune-related risk in proportion; it may simply give less of a treatment that was working. So the standard approach is to pause rather than to shrink.
A cycle held because of a blood result or a symptom is routine practice, not a setback, and it is one of the commonest sources of unnecessary anxiety in a day-care waiting room. Ask what the plan is for restarting; there usually is one.
Symptoms that need urgent assessment, not a dose conversation: new or worsening breathlessness, or a persistent dry cough; loose motions that increase in number or contain blood; chest pain or palpitations; severe unexplained fatigue with dizziness, vomiting or collapse; yellowing of the eyes or skin. For any of these, contact your treating oncology team immediately or go to the nearest emergency department. Do not self-medicate and do not wait for the next scheduled cycle.
Never adjust, delay, split or stop a dose on your own initiative, and never on cost grounds without saying so. An improvised schedule can undo the treatment and confuse the interpretation of every scan that follows. If cost is the obstacle, say it plainly to the treating team; it is a conversation they have often.
Immunotherapy Dose Calculation: Frequently Asked Questions
Why is the pembrolizumab dose 200 mg for everyone?
Because past a certain exposure, more drug does not add effect. Pembrolizumab was originally studied at doses set per kilogram of body weight. Modelling of that trial data, including published work by Freshwater and colleagues in 2017, found that a fixed 200 mg dose and a 2 mg/kg dose produced similar drug-exposure distributions with no advantage to either approach. Regulators accepted the fixed dose because it is simpler to prepare, quicker to check and removes a calculation step where errors happen. The current adult convention is 200 mg every three weeks or 400 mg every six weeks.
Does my body weight change my immunotherapy dose?
For most single-agent checkpoint inhibitors given to an adult, no. The fixed dose is the same at 50 kg and at 90 kg. Weight still decides the dose in four situations: molecules that kept weight-based dosing, such as ipilimumab and serplulimab; some combination regimens; adults below a stated body-weight threshold, which is 30 kg on the durvalumab label; and children, whose dosing remains weight-based even where the adult dose is fixed. If your weight changes substantially during treatment, tell your team rather than assuming the dose should follow.
Why is chemotherapy dosed by body size but immunotherapy is not?
Because the two kinds of drug behave differently. A cytotoxic chemotherapy drug has a narrow margin between an effective dose and a harmful one, so scaling the dose to body surface area matters. A monoclonal antibody such as a checkpoint inhibitor distributes more predictably, has a wide margin, and reaches a ceiling of effect once the PD-1 receptor is essentially fully occupied. Above that point, extra antibody blocks nothing further. Scaling it to body size adds arithmetic without changing the outcome, so most labels moved to a fixed dose.
Does flat dosing mean a lighter patient pays more than they need to?
In drug terms, yes, and it is a fair objection. Under a per-kilogram convention a lighter patient would have needed less drug and fewer vials. Fixed dosing removed that difference, so a 50 kg patient now buys the same number of vials as a 90 kg patient. Published economic analyses have made this point for years. Regulators weighed it against fewer preparation errors, faster pharmacy turnaround and the flat exposure-response relationship, and settled on fixed dosing. The treatment interval and the non-drug charges usually affect a total bill more than the dosing convention does.
Why does the vial size matter for what a cycle costs?
Because these medicines are bought and billed by the vial, not by the milligram, and a dose is made up from whole vials. Several checkpoint inhibitors come in 100 mg vials, which is why so many conventional doses are round multiples of 100 mg. Where a dose does not divide neatly into the available vials, the remainder is usually paid for and usually discarded, because an opened single-dose vial has a short window and strict handling conditions. Some hospital pharmacies run a formal dose-banding arrangement to reduce that waste; many cannot.
Can an immunotherapy dose be reduced if I get side effects?
Generally not in the way a chemotherapy dose is reduced. For immune checkpoint inhibitors, side effects are usually managed by holding the next dose, treating the inflammation and then deciding whether to restart, rather than by giving a smaller amount of the same drug. A cycle held because of a blood result or a new symptom is routine practice, not a setback. Never adjust, delay, split or stop a dose on your own initiative, and never on cost grounds without telling the treating team. If cost is the obstacle, say so plainly; it is a conversation an oncology team has often.